Dogwood Therapeutics, Inc (NASDAQ:DWTX – Free Report) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Dogwood Therapeutics in a research note issued to investors on Thursday, March 19th. HC Wainwright analyst S. Lee forecasts that the company will post earnings of $2.29 per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share.
Other equities research analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. Wall Street Zen cut shares of Dogwood Therapeutics to a “strong sell” rating in a research report on Saturday, December 13th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.00.
Dogwood Therapeutics Stock Up 10.7%
Dogwood Therapeutics stock opened at $3.00 on Friday. The company has a market capitalization of $100.20 million, a PE ratio of -0.16 and a beta of 1.90. Dogwood Therapeutics has a 12-month low of $2.60 and a 12-month high of $9.50. The firm’s fifty day moving average is $2.95 and its 200 day moving average is $4.66.
Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.96.
Hedge Funds Weigh In On Dogwood Therapeutics
An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is currently owned by institutional investors and hedge funds.
More Dogwood Therapeutics News
Here are the key news stories impacting Dogwood Therapeutics this week:
- Positive Sentiment: HC Wainwright raised multiple 2026 quarterly and full‑year EPS forecasts (Q1–Q4 2026 and FY2026) and boosted FY2027–FY2028 outlooks while keeping a “Buy” rating and a $12 price target — this improves near‑term profitability visibility and likely supported today’s buying interest. HC Wainwright raises estimates
- Positive Sentiment: Dogwood reported Q4 and full‑year 2025 financial results, with Q4 EPS (‑$0.26) beating Street expectations (consensus ~‑$1.22) — an earnings beat that provides immediate fundamental support. Dogwood Reports Q4 and FY2025 Results
- Neutral Sentiment: HC Wainwright published a long‑range FY2030 EPS projection ($2.29), which is bullish if realized but far‑out and speculative for valuation today. HC Wainwright FY2030 estimate
- Neutral Sentiment: Short interest data in the most recent release appears anomalous (reported as zero with NaN changes), suggesting no clear short‑selling pressure signal from that data point.
- Negative Sentiment: HC Wainwright trimmed its FY2029 EPS forecast (from $1.13 to $0.72), a sign that some long‑range assumptions were moderated — this could cap upside for longer‑dated valuation scenarios. HC Wainwright lowers FY2029 estimate
About Dogwood Therapeutics
Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.
Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.
Further Reading
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
